Seeking Alpha

The FDA grants Synageva BioPharma (GEVA) Breakthrough Therapy designation for sebelipase alfa, a...

The FDA grants Synageva BioPharma (GEVA) Breakthrough Therapy designation for sebelipase alfa, a treatment for early onset acid lipase deficiency. Earlier this month, JPMorgan expressed some skepticism based on what the bank says is a fairly low level of disease awareness (even among specialists). (PR)
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs